# ON BEHALF OF NIAID-DCR, FACILITATE THE CONDUCT OF TWO, RANDOMIZED TRIALS AS DETAILED BELOW IN I AND II:I.	A RANDOMIZED BLINDED CONTROLLED TRIAL OF TH

> **NIH NIH N01** · LEIDOS BIOMEDICAL RESEARCH, INC. · 2020 · $67,359,812

## Abstract

This funding supports INSIGHT Protocol Number: 013, Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC).  It is an international multicenter, adaptive, randomized double-blind, placebo-controlled trial of the safety, tolerability, and efficacy of anti-coronavirus hyperimmune intravenous immunoglobulin for the treatment of adult hospitalized patients at the onset of clinical progression of COVID-19.

## Key facts

- **NIH application ID:** 10280864
- **Project number:** 75N91019D00024-0-759102000009-1
- **Recipient organization:** LEIDOS BIOMEDICAL RESEARCH, INC.
- **Principal Investigator:** BETH BASELER
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $67,359,812
- **Award type:** —
- **Project period:** 2020-04-03 → 2025-04-02

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10280864

## Citation

> US National Institutes of Health, RePORTER application 10280864, ON BEHALF OF NIAID-DCR, FACILITATE THE CONDUCT OF TWO, RANDOMIZED TRIALS AS DETAILED BELOW IN I AND II:I.	A RANDOMIZED BLINDED CONTROLLED TRIAL OF TH (75N91019D00024-0-759102000009-1). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10280864. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*